Even so, the institution's Scientific Management Review Board, a panel of NIH officials and outside scientists, voted 12-1 in December 2010 to establish the center, endorsing the findings of Rubenstein's group (http://smrb.od.nih.gov/dec/TMAT_Meeting_Formatted.pdf).
As planned, the center will administer the Cures Acceleration Network, a stillunfunded creation of President Barack Obama's health reform law that is aimed at supporting rapid deployment of high-need cures. The center will also house the agency's molecular libraries screening program, the government's initiative for rare and neglected diseases and its Clinical and Translational Science Awards, a grant program worth some US$490 million a year.
"The idea was really to coordinate, streamline and bring the best brains together," Rubenstein says, tapping agencies "that have been trying to do the same thing, but not very successfully."
The proposal is in the hands of Health and Human Services Secretary Kathleen Sebelius, who will pass it on to Congress while the administration's accountants examine implications for the budget. Collins hopes to have the new center running by the fall.
Federal law limits the NIH to 27 institutes, which it already has. Collins is steering a parallel proposal to combine the agency's alcohol and drug abuse institutes, which would free up a slot. If that doesn't happen in time, Congress would need to approve a temporary workaround.
John Burklow, Collins' spokesman, says he sees no particular red flags in the road ahead. But he cautions that there is no clear precedent for bringing this center into being because it is being driven by scientists instead of the usual sponsors, legislators.
About 95% of researched drugs ultimately prove to be ineffective or unsafe, and failure often comes late in the game after millions have been spent and a succession of preclinical tests and clinical trials has unfolded. Successful drugs take an average of eight years to reach the market.
No wonder buzzwords such as "quick-win" and "fast-fail" are taking hold among proponents of translational research.
"It is time for a new view and not an incremental tweak," Collins told his staff in December. "It is clear that scientific advances, many supported by NIH, are providing new insights into the molecular causes of disease at a dizzying rate. And many of these insights are potentially actionable, suggesting new approaches to prevention or treatment that need to be tested."
Yet the "long timelines between such ideas and their reaching the market are frustrating and sometimes they never get there at all," he added (http://feedback.nih.gov/index.php/category/ncats/ncats-updates/).
The hurry-up impulse at work in the NIH is spreading in academia, too. In May 2010, Andy Grove, former CEO and chairman of Intel Corp., pledged US$1.5 million to start a master's program in translational medicine at the University of California.
Dealing with his own prostate cancer and now Parkinson's disease over more than a decade, the entrepreneur became an impatient patient, frustrated that science could heal lab mice but fail people. He set out to instill the engineering and marketing drive of Silicon Valley in medical research.
